NervGen Pharma Corp. NGEN
NervGen Pharma Corp. (Nasdaq: NGEN) is a CNS/neurology/psychiatry drug developer. Its lead program, NVG-291, is in Phase 2 for Spinal cord injury (chronic and subacute tetraplegia).
Upcoming catalysts
No catalyst is dated to the next 30 days or to an FDA action date.
Pipeline
| Program | Indication | Modality | Stage |
|---|---|---|---|
| NVG-291 (CONNECT SCI Phase 1b/2a, chronic and subacute cohorts) | Spinal cord injury | protein/peptide | Phase 2 |
| NVG-300 | Neurotraumatic/neurologic conditions (SCI, stroke models) | protein/peptide | Pre-clinical |
Recent results and decisions
- Oct 16, 2026clinical hold NVG-291 for SCI is currently subject to a partial clinical hold by the FDA.
NVG-291 for SCI is currently subject to a partial clinical hold by the FDA, and we may be unable to have the hold removed
Filing - Oct 16, 2026clinical hold NVG-291 for SCI is currently subject to a partial clinical hold by the FDA.
NVG-291 for SCI is currently subject to a partial clinical hold by the FDA, and we may be unable to have the hold removed which could adversely affect development of NVG-291 and our results of operations
Filing - Oct 16, 2026n/a NervGen is preparing to initiate a Phase 3 clinical trial for NVG-291 in chronic tetraplegia.
we are preparing to initiate a Phase 3 clinical trial for chronic tetraplegia
Filing
1 more on record.
For subscribers
- Cash runway against each catalyst, with the company's own runway statement
- Track record: every Phase 3 readout, FDA decision and guidance slip since 2014
- Expected move for each dated catalyst, from comparable past events
- Phase 2 evidence behind each Phase 3 readout
- Companies on the same target or class
- Full catalyst list with filing sentences, deals, registered trials, Excel export
Other phase 2 CNS/neurology/psychiatry companies
The free Monday brief
Last week's readouts and FDA decisions and the dated catalysts in the week ahead, each with its filing sentence.